A61K 40/4272
Melan-a/mart
Official title: {Melan-A/MART}
A61K40/4272 (Melan-a/mart) appears on 179 US grants and 325 published applications in this corpus.
Search patents in A61K- Granted patents
- 179
- Published applications
- 325
- Assignees
- 173
- Inventors
- 521
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 2 |
| 2004 | 3 | 16 |
| 2005 | 1 | 5 |
| 2006 | 1 | 9 |
| 2007 | 1 | 5 |
| 2008 | 4 | 11 |
| 2009 | 3 | 12 |
| 2010 | 6 | 8 |
| 2011 | 9 | 5 |
| 2012 | 5 | 11 |
| 2013 | 9 | 2 |
| 2014 | 4 | 13 |
| 2015 | 6 | 9 |
| 2016 | 6 | 12 |
| 2017 | 7 | 27 |
| 2018 | 10 | 13 |
| 2019 | 15 | 25 |
| 2020 | 10 | 25 |
| 2021 | 15 | 21 |
| 2022 | 11 | 26 |
| 2023 | 12 | 21 |
| 2024 | 11 | 15 |
| 2025 | 15 | 21 |
| 2026 | 11 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cancer antigens and methods14 Jul 2026US 12,680,105 B2Enara Bio Limited
- Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood19 May 2026US 12,630,802 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Tethered interleukin-15 and interleukin-215 May 2026US 12,617,833 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy28 Apr 2026US 12,612,598 B2Iovance Biotherapeutics, Inc.
- Compositions and methods for making novel T-cell receptors21 Apr 2026US 12,606,936 B2VCreate, Inc.
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
- Tethered interleukin-15 and interleukin-2117 Sep 2026US 2026/0274917 A1The United States of America, as represented by the Secretary, Department of Health and Human Servi
- Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy3 Sep 2026US 2026/0258358 A1Board of Regents, The University of Texas System
- Plasmacytoid dendritic cells and immune checkpoint inhibitor for cancer treatment13 Aug 2026US 2026/0232798 A1Pdc Line Pharma
- Tethered interleukin-15 and interleukin-212 Jul 2026US 2026/0184760 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
Most cited
By later US patents
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy98US 8,287,857 B2The United States of America as represented by the Secretary of the Deparment of Health and Human Services · 2012
- Melanoma antigens and their use in diagnostic and therapeutic methods30US 6,537,560 B1The United States of America as represented by the Department of Health and Human Services · 2003
- Sensitization process for antigen-presenting cells and means for implementing the process29US 6,685,911 B1Centre National De La Recherche Scientifique · 2004
- Melanoma vaccine and methods of making and using same28US 7,015,205 B1St. Vincent's Hospital and Medical Center of New York · 2006